Results 81 to 90 of about 2,285,924 (374)

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.

Blood, 2019
Anemia of lower-risk myelodysplastic syndromes (MDSs) and primary myelofibrosis (PMF) generally becomes resistant to available treatments, leading to red blood cell (RBC) transfusions, iron overload, shortened survival, and poor quality of life.
P. Fenaux, J. Kiladjian, U. Platzbecker
semanticscholar   +1 more source

Angiogenesis in myelodysplastic syndromes [PDF]

British Journal of Cancer, 1999
It is now well established that solid tumour growth depends on angiogenesis. However, less is known about the generation of new vessels in haematological malignancies and, in particular, in preleukaemic-myelodysplastic syndromes (MDS). In this study, bone marrow microvessel density (MVD) was assessed by immunohistochemistry and compared in trephine ...
G. Pruneri, F. Bertolini, D. Soligo, N. Carboni, A. Cortelezzi, P. F. Ferrucci, R. Buffa, G. Lambertenghi-Deliliers, F. Pezzella   +8 more
openaire   +4 more sources

Myelodysplastic Syndromes and Metabolism

International Journal of Molecular Sciences, 2021
Myelodysplastic syndromes (MDS) are acquired clonal stem cell disorders exhibiting ineffective hematopoiesis, dysplastic cell morphology in the bone marrow, and peripheral cytopenia at early stages; while advanced stages carry a high risk for transformation into acute myeloid leukemia (AML).
Ekaterina Balaian, Manja Wobus, Martin Bornhäuser, Triantafyllos Chavakis, Katja Sockel   +4 more
openaire   +3 more sources

Identification of a Proteolysis‐Targeting‐Chimera that Addresses Activated Checkpoint Kinase‐1 Reveals its Non‐Catalytic Functions in Tumor Cells

Angewandte Chemie International Edition, EarlyView.
In cancer cells, the induction of DNA replication stress by HU activates CHK1 by autophosphorylation. This leads to cell cycle arrest and recruits the DNA repair protein WRN to promote DNA repair and cell survival. In such cells, addition of the CHK1 inhibitor 9a propels DNA damage and apoptosis.
Ramy Ashry, Mohamed Abdelsalam, Julia Hausen, Christoph Hieber, Yanira Zeyn, Anne‐Christin Sarnow, Matthias Schmidt, Sara Najafi, Ina Oehme, Matthias Bros, Jia‐Xuan Chen, Mario Dejung, Wolfgang Sippl, Oliver H. Krämer   +13 more
wiley   +1 more source

Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

Haematologica, 2012
Background There are limited reports of thrombosis among myelodysplastic syndrome patients exposed to erythropoiesis stimulating agents. It is not clear whether erythropoiesis stimulating agents are associated with an increased risk of thrombosis in ...
Sheila Weiss Smith, Masayo Sato, Steven D. Gore, Maria R. Baer, Xuehua Ke, Diane McNally, Amy Davidoff   +6 more
doaj   +1 more source

Preleukemia: one name, many meanings. [PDF]

, 2017
Definition of preleukemia has evolved. It was first used to describe the myelodysplastic syndrome (MDS) with a propensity to progress to acute myeloid leukemia (AML). Individuals with germline mutations of either RUNX1, CEBPA, or GATA2 can also be called
Koeffler, HP, Leong, G
core  

Value of infliximab (Remicade) in patients with low-risk myelodysplastic syndrome. Final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group [PDF]

, 2011
peer reviewedTumor-necrosis factor alpha activity has been correlated to ineffective erythropoiesis in lower risk myelodysplastic syndromes. Infliximab (Remicade) is an anti-tumor-necrosis factor alpha chimeric antibody that is used in the treatment of ...
Amadori, Sergio, Baron, Frédéric, De Witte, Theo, Delforge, Michel, Denzlinger, Claudio, Indrak, Karel, Muus, Petra, Ossenkoppele, Geert, Selleslag, Dominik, Suciu, Stefan, Thyss, Antoine, Zwierzina, Heinz   +11 more
core   +2 more sources

Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.

Hematology. American Society of Hematology. Education Program, 2020
Myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes are uniquely classified neoplasms occurring in both children and adults.
M. Patnaik, T. Lasho
semanticscholar   +1 more source

Epigenetics in myelodysplastic syndromes [PDF]

Seminars in Cancer Biology, 2018
Epigenetic regulators are the largest group of genes mutated in MDS patients. Most mutated genes belong to one of three groups of genes with normal functions in DNA methylation, in H3K27 methylation/acetylation or in H3K4 methylation. Mutations in the majority of epigenetic regulators disrupt their normal function and induce a loss-of-function ...
Heuser, Michael, Yun, Haiyang, Thol, Felicitas   +2 more
openaire   +2 more sources

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

Arthritis &Rheumatology, EarlyView.
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian, Sophie Georgin‐Lavialle, Marcela A. Ferrada, Sinisa Savic, Matthew J. Koster, Olivier Kosmider, Thibault Comont, Mael Heilblig, Juan I. Arostegui, Annmarie Bosco, Rim Bourguiba, Katherine R. Calvo, Catherine Cargo, Chiara Cattaneo, François Chasset, Henrique Coelho, Corrado Campochiaro, Francesca Crisafulli, Stephanie Ducharme‐Benard, Raquel Faria, Franco Franceschini, Micol Frassi, Emma M. Groarke, Carmelo Gurnari, Yervand Hakobyan, Yvan Jamilloux, Ciprian Jurcut, Yohei Kirino, Austin Kulasekararaj, Hiroyoshi Kunimoto, Lauren M. Madigan, Heřman F. Mann, Chiara Marvisi, Marcin Milchert, Sara Morais, Katja Sockel, Francesco Muratore, Hideaki Nakajima, Mrinal M. Patnaik, Luísa Regadas, Marie Robin, Abraham Rutgers, Carlo Salvarani, Anthony M. Sammel, Joerg Seebach, Pierre Sujobert, Alessandro Tomelleri, Geoffrey Urbanski, Frédéric Vandergheynst, Romana Vieira, David S. Viswanatha, Ewa Więsik‐Szewczyk, Elisa Diral, Benjamin Terrier, Bhavisha A. Patel, Pierre Fenaux, Peter C. Grayson, David B. Beck, on behalf of the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological Diseases, Heřman Mann, Benjamin Terrier, François Chasset, Sophie Georgin Lavialle, Alessandro Tomelleri, Campochiaro Corrado, Carlo Salvarani, Francesca Crisafulli, Franco Franceschini, Micol Frassi, Yohei Kirino, Ewa Więsik‐Szewczyk, Marcin Milchert, Raquel Faria, Ciprian Jurcut, Joerg Seebach, Sinisa Savic, David Beck, Lauren Madigan, Matthew Koster, Patnaik Mrinal, Olivier Kosmider, Pierre Sujobert, Juan I. Arostegui, Catherine Cargo, David Viswanatha, Yervand Hagopian, Mael Heilblig, Pierre Fenaux, Thibault Comont, Bruno Alessandro, Chiara Cattaneo, Elisa Diral, Sara Morais, Austin Kulasekarara, Emma Groarke, Katherine Calvo, Patel Bhavisha, Anthony Sammel, Arsene Mekinian, Benjamin Terrier, Marie Robin, Sophie Georgin Lavialle, Katja Sockel, Yvan Jamilloux, Carmelo Gurnari, Henrique Coelho, Romana Vieira, Rim Bourguiba, Marcela Ferrada, Peter Grayson   +111 more
wiley   +1 more source